Related Experiment Video
Updated: Jul 6, 2026

Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
Lipid Changes 10-15 Years After Roux-en-Y Gastric Bypass: A Prospective Observational Study
Eirin Rosø Barkhall1, Johanne Tro2, Jorunn Sandvik3,4,5
1Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway. eirin.roso.barkhall@helse-mr.no.
Background:
Several studies have documented a beneficial short-term effect on lipid profile after Roux-en-Y gastric bypass (RYGB), but there is limited data on long-term changes.
Objectives:
To describe long-term (> 10 years) changes in lipid profile after RYGB and to explore the relationship of lipid changes to changes in weight and baseline and demographic parameters.
Methods:
The BAROBS study is a prospective observational study post RYGB conducted at three different hospitals. Surgical procedures were performed between 2003 and 2009, and the collection of data was in 2018-2020. Data on lipid profile, weight, body mass index (BMI), percentage of total weight loss (%TWL), and pre- and postoperative type II diabetes mellitus (DMII) was collected at baseline, 1-2, 5, and 10 years post-surgery and was available for 314 of 546 patients in the study.
Results:
The mean (SD) follow-up was 11.5(± 1.5) years, with a mean reduction of 11.7% for LDL, 29.7% for TG, and 7.7% for total cholesterol compared to baseline. Except for HDL and total-/HDL-cholesterol-ratio, all lipid variables reached their greatest change after 1-2 years with an attenuation of changes at end of study. HDL and total-/HDL-cholesterol-ratio had stable values from 5 to 10 years post-surgery. Lipid profile improved more in patients with greater weight loss. There was a 59% reduction in DMII at end of study, and there was a significant relation between preoperative DMII and long-term lipid values.
Conclusion:
There is an improvement of all lipid parameters after 10 years post RYGB related to both the magnitude of weight loss and the presence of DMII.

